Current Partners
Mitsubishi Tanabe Alliance
Announced on December 13, 2010, Anaphore and Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) entered into a collaboration for the research, development and commercialization of novel protein therapies for autoimmune disease. The partnership is based on Anaphore’s proprietary platform technology, which generates novel trivalent proteins with binding domains that can be programmed to bind to and activate or inhibit nearly any target of interest. The agreement stipulates an initial target for the research program. Tanabe Research Laboratories U.S.A., Inc. (TRL), a San Diego-based subsidiary of Mitsubishi Tanabe Pharma, has the option to nominate two additional autoimmune targets against which Anaphore would develop potential protein therapeutics.
